| Followers | 2 |
| Posts | 24 |
| Boards Moderated | 0 |
| Alias Born | 01/08/2020 |
Wednesday, March 08, 2023 10:51:20 AM
New article out on Zerohedge highlighting ProLectin. Drug is pretty promising. Especially since the ritonavir in Paxlovid means that Paxlovid won't be a good idea for long COVID. ProLectin is the best approach for Long COVID I've seen. But also potentially the best antiviral for acute COVID too, as explained in the article.
https://www.zerohedge.com/news/2023-03-07/sick-jabs-and-rebounds-breakthrough-antiviral-flushes-out-multiple-viruses
https://www.zerohedge.com/news/2023-03-07/sick-jabs-and-rebounds-breakthrough-antiviral-flushes-out-multiple-viruses
Bullish
Recent BIXT News
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/15/2026 05:28:48 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 04/15/2026 08:01:16 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 04/01/2026 10:23:52 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/20/2026 01:05:14 PM
- BIOXYTRAN, INC. COMPLETES $1.2 MILLION PRIVATE PLACEMENT • GlobeNewswire Inc. • 03/20/2026 01:05:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/13/2026 08:00:24 PM
- Bioxytran Announces Positive Dose Optimization Results and Advances Toward Phase 3 Registrational Trial for ProLectin-M • GlobeNewswire Inc. • 03/04/2026 08:40:00 PM
- Bioxytran, Inc. Reports Positive Phase 1b/2a Clinical Study Results for ProLectin-M, a Broad-Range Antiviral Drug in Mild to Moderate COVID-19 • ACCESS Newswire • 03/02/2026 04:40:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/02/2026 02:22:23 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/17/2026 11:20:29 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/11/2026 11:04:17 AM
- Bioxytran Reports Positive Phase 2 Results Demonstrating Rapid Viral Clearance with ProLectin-MBioxytran • GlobeNewswire Inc. • 02/11/2026 11:00:00 AM
- Bioxytran and University of Minnesota Launch Sponsored Research Collaboration to Advance Novel Carbohydrate-Based Therapeutics • GlobeNewswire Inc. • 02/02/2026 12:00:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/05/2026 10:01:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 12/15/2025 11:15:32 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:15:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/18/2025 09:02:52 PM
- Form 4/A - Statement of changes in beneficial ownership of securities: [Amend] • Edgar (US Regulatory) • 11/18/2025 06:12:20 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2025 09:00:57 PM
- Bioxytran Announces Initiation of Coverage of its Stock by Independent Research • GlobeNewswire Inc. • 11/13/2025 06:50:00 PM
- Bioxytran Completes Randomized Clinical Trial For its Broad-Spectrum Antiviral Drug • GlobeNewswire Inc. • 10/29/2025 01:30:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 08/11/2025 11:01:03 AM
